Biogen Skids On ' Low-Quality ' Beat, Profit Guidance Haircut

stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But analysts zeroed in on its strong launch for a Friedreich's ataxia drug. Biogen acquired the Friedreich's ataxia treatment, Skyclarys, along with Reata Pharmaceuticals for about $7.3 billion. Friedreich's ataxia…#biogen #reatapharmaceuticals #rbccapitalmarkets #brianabrahams #wedbush #laurachico #mizuhosecurities #salimsyed #rbc #abrahams

Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news